Another one bites the dust as Novartis, Amgen and the Banner Alzheimer’s Instituteannounced they are halting two pivotal Phase II/III clinical trials in the Alzheimer’s Prevention Initiative Generation Program.
The trials were evaluating the BACE1 inhibitor CNP520 (umibecestat). An analysis of unblinded data during a scheduled review showed that the patients were getting worse in some of the measurements of cognitive function, the opposite of what they were hoping. The sponsors all decided that any patient benefit wasn’t worth the risk.
“Novartis has a strong research focus and commitment to patients,” stated John Tsai, head of Global Drug Development and chief medical officer of Novartis. “As researchers we have to accept today’s disappointing news as part of the search for innovative new treatments. We remain committed to advancing science in Alzheimer’s disease and continue to seek future solutions for people with neurodegenerative conditions.”
The Amgen and Novartis Neuroscience Collaboration launched in August 2015 to develop and market treatments for migraine and Alzheimer’s disease. Amgen and Novartis sponsor the work in collaboration with Banner Alzheimer’s Institute. Novartis is the regulatory sponsor and Amgen and Novartis are co-development partners.
The companies indicate they hope to continue data analysis to better understand the disease and will present anything relevant at a future scientific meeting.
The failure of BACE inhibitors is just another argument against the amyloid theory of Alzheimer’s disease. Beta-amyloid is a protein that is found accumulating in the brains of Alzheimer’s patients. It has long been thought that the protein was the cause of the memory and cognitive issues in the disease, but dozens of clinical trials that successfully cleared or halted the production of beta-amyloid failed to make a difference in the patients’ clinical conditions.
BACE1 inhibitors like umibecestat don’t break up or clear amyloid, but block BACE1, an enzyme that helps form amyloid plaques. But BACE inhibitors have failed to make a difference as well. In 2017, Merck gave up on its BACE inhibitor verubecestat. Eisai and Biogen are continuing to work on their BACE inhibitor elenbecestat, after an independent board recommending that two Phase III trials of it continue.
But this year alone has marked to prominent failures in the Alzheimer’s arena. Roche and AC Immune gave on their crenezumab in January after an interim analysis of Phase III data. And in March, Biogen halted its late-stage trials of aducanumab after independent analysis concluded the trials would fail.
